Bioluminescent Biosensor for Hippo Pathway Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the capability to monitor the dynamics and activity of the Hippo signaling pathway components in a quantitative, high-throughput, and non-invasive manner, limiting understanding and intervention in related diseases such as cancer.
Innovation Solution
Development of a bioluminescent biosensor system using fragments of firefly or NanoBiT luciferase and human YAP or its equivalents, combined with vectors, to non-invasively monitor LATS kinase and YAP-TEAD interactions, enabling real-time quantification of Hippo pathway activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional methods are used to study Hippo pathway components, then research can be conducted with existing tools, but the ability to monitor dynamics and activity in a quantitative, high-throughput, and non-invasive manner is limited
Solution Approach 1:
The luciferase enzyme is divided into two non-functional fragments (Nluc and Cluc) that can only restore activity when bound to each other. The Nluc fragment is fused to YAP while Cluc is fused to 14-3-3, so that Hippo pathway activation brings the fragments together to produce measurable luminescence signal.
Solution Approach 2:
The 14-3-3 protein serves as an intermediary that mediates the interaction between phosphorylated YAP and the Cluc fragment. When LATS phosphorylates YAP, the phosphorylated YAP binds to 14-3-3, which in turn brings Cluc into proximity with Nluc to restore luciferase activity and generate the luminescence signal.
2Reliability
If invasive methods are used to measure Hippo pathway activity, then quantitative data can be obtained, but the monitoring process becomes invasive and limits real-time observation
Solution Approach 1:
The patent replaces mechanical/invasive measurement methods with a biochemical-optical system. The split luciferase system converts protein-protein interaction events into luminescence signals that can be detected non-invasively using standard imaging equipment, eliminating the need for cell lysis or other invasive procedures.
Solution Approach 2:
The system utilizes bioluminescence (light emission) as a readout for Hippo pathway activity. When the luciferase fragments are brought together through protein interaction, they catalyze a chemical reaction that emits light, providing a non-invasive optical signal that can be monitored in real-time without affecting cell viability.
3Productivity
If comprehensive regulator screens are performed, then complete understanding of Hippo pathway regulation can be achieved, but technical limitations prevent high-throughput analysis
Solution Approach 1:
The patent optimizes several parameters to enable high-throughput screening: the split luciferase system provides high signal-to-noise ratio for sensitive detection, the phosphorylation-dependent binding mechanism ensures specific response to Hippo pathway activation, and the modular construct design allows easy adaptation to different screening formats and conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biosensor system allows for accurate, real-time monitoring of Hippo signaling pathway activity, providing insights into disease mechanisms and potential therapeutic targets with high sensitivity and reproducibility.
Implementation Method 1
LATS-dependent phosphorylation of the at least one YAP fragment leads to binding with the human cytoplasmic 14-3-3 protein, which results in binding of Nluc and Cluc to produce luminescence
Data Source
AI summary
Bioluminescent biosensors useful for monitoring and/or quantifying, in vitro or in vivo, activity of the Hippo signaling pathway. The biosensors monitor LATS kinase activity or YAP-TEAD interaction. The biosensors may be used in methods for monitoring and/or quantifying in real-time, in vitro or in vivo, activity of the Hippo signaling pathway, wherein the activity may be LATS kinase activity and/or YAP-TEAD interaction. The biosensors may be provided in kits for monitoring and/or quantifying in real-time, in vitro or in vivo, activity of the Hippo signaling pathway, wherein the activity may be LATS kinase activity and/or YAP-TEAD interaction.